A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPLINDSAY, C.VELUSWAMY, R.CASTRO JUNIOR, G.TAN, D. Y. H.CAPARICA, R.GLASER, S.MALHOTRA, S.FELIP, E.CHAN, E.2024-03-082024-03-082024INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, v.118, n.1, p.E13-E14, 20240360-3016https://observatorio.fm.usp.br/handle/OPI/58525engrestrictedAccessA Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-MutationconferenceObjectCopyright ELSEVIER SCIENCE INCOncologyRadiology, Nuclear Medicine & Medical Imaging1879-355X